RE:RE:Will THTX backtrack from these statements??Wow! Now I learned that the management of the company is likely dishonest. But you still think that the stock of a company likely lying on important financial stuff is undervalued. You are hard to follow... But I finally got it, the stock price is so undervalued because the market cannot trust a management that likely lies on important matters. So if they lied there, why not on oncology potential, why not on NASH real approval potential?
So oncology has zero value, the management likely lied on sales growth, they are blowing up their credibility with investors. I now understand why some are pushing for a CYDY pumping approach. In fact, what you are asking the management is this: don't just lie a bit, if you are to lie, lie the whole way. Pump the stock price out of nothing so we can sell.
All that is not serious. The level of bitterness here is out of control.
SPCEO1 wrote: They already backtracked last quarter on the sales growth statement. I forget the exact wording but it was something that suggested tepid growth short term and better growth long term. My belief is that the 20-25% projection was made just to support the OO. They knew it was nonsense at the time. So, yes management likely lied to investors about that and then quickly retracted it when Q1's ugly results were released. You may remember me fuming about them blowing up their credibility with investors again.
longterm56 wrote: Although TXTH has been very tight-lipped (wow, that's an understatement), there are two statements directly from Paul that he has not yet retracted or modified (from what I recall):
- NASH trial to begin in 3rd quarter
- 20-25% Q/Q growth of revenues from Egrifta & Trogarzo.
We'll see if he comments on or retracts either of these on Thursday.
-LT